Abstract
Transmission chains within cities provide an important contribution to case burden and economic impact during the ongoing COVID-19 pandemic, and should be a major focus for preventive measures to achieve containment. Here, at very high spatio-temporal resolution, we analysed determinants of SARS-CoV-2 transmission in a medium-sized European city. We combined detailed epidemiological, mobility, and socioeconomic data-sets with whole genome sequencing during the first SARS-CoV-2 wave. Both phylogenetic clustering and compartmental modelling analysis were performed based on the dominating viral variant (B.1-C15324T; 60% of all cases). Here we show that transmissions on the city population level are driven by the socioeconomically weaker and highly mobile groups. Simulated vaccination scenarios showed that vaccination of a third of the population at 90% efficacy prioritising the latter groups would induce a stronger preventive effect compared to vaccinating exclusively senior population groups first. Our analysis accounts for both social interaction and mobility on the basis of molecularly related cases, thereby providing high confidence estimates of the underlying epidemic dynamics that may readily be translatable to other municipal areas.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04351503
Funding Statement
No dedicated funding was used for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was given by the local ethical committee Ethik Kommission Nordwest und Zentralschweiz (EKNZ No. 2020-00769, to be found at https://ongoingprojects. swissethics.ch) and the project was registered at clinicaltrial.gov under NCT04351503.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵+ These authors share senior authorship
correction of author names in the PDF as well as addition of a supplementary file acknowledging the to GISAID contributing labs.
Data Availability
The SEIR-model code used for this submission will be available on https://github.com/BorgwardtLab/BaselEpi.git. Code that was used for phylogenetic inference and calculation of significance of clusters in specified groups is available at https://github.com/appliedmicrobiologyresearch. SARS-CoV-2 whole genomes from Basel-City are available at gisaid.com and at European Nucleotide Archive (ENA) under accession number PRJEB39887.
